Comparative Pharmacology
Head-to-head clinical analysis: HERNEXEOS versus TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HERNEXEOS versus TRIFLURIDINE.
HERNEXEOS vs TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC). The antibody binds to HER2 on tumor cells, leading to internalization and intracellular release of the topoisomerase I inhibitor payload (DXd), which causes DNA damage and apoptosis.
Trifluridine is a thymidine analog that inhibits thymidylate synthase and incorporates into DNA, leading to DNA damage and cell death.
2.5 mg subcutaneously once daily.
Topical: Apply one drop to affected eye every 2 hours while awake (maximum 9 drops/day) until re-epithelialization, then one drop every 4 hours for 7 days. Ophthalmic solution 1%.
None Documented
None Documented
Terminal elimination half-life: 12 hours; clinical context: allows twice-daily dosing in most patients; renal impairment prolongs half-life up to 24 hours
Clinical Note
moderateTrifluridine + Digoxin
"Trifluridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrifluridine + Digitoxin
"Trifluridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrifluridine + Deslanoside
"Trifluridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrifluridine + Acetyldigitoxin
"Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of trifluridine is approximately 12-18 hours. This prolonged half-life supports twice-daily dosing and provides sustained exposure for antiviral activity.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other routes
Renal excretion accounts for approximately 40-50% of the administered dose, primarily as the inactive metabolite 5-trifluorothymidine. Fecal excretion is minimal (<5%). The remainder is eliminated via metabolic degradation.
Category C
Category C
Antiviral
Antiviral